Provided by Tiger Trade Technology Pte. Ltd.

Vir Biotechnology, Inc.

9.78
+0.57006.19%
Post-market: 9.780.00000.00%19:30 EDT
Volume:1.76M
Turnover:17.03M
Market Cap:1.65B
PE:-5.76
High:9.86
Open:9.31
Low:9.31
Close:9.21
52wk High:11.66
52wk Low:4.35
Shares:168.65M
Float Shares:130.00M
Volume Ratio:1.24
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6972
EPS(LYR):-3.1619
ROE:-26.08%
ROA:-14.51%
PB:1.68
PE(LYR):-3.09

Loading ...

Vir Biotechnology Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 24

Stocks to Watch: Diamondback Energy, Hims & Hers, Vir Bio, Whirlpool

Dow Jones
·
Feb 24

Vir Biotechnology Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
Feb 24

Vir Biotechnology Q4 revenue beats estimates

Reuters
·
Feb 24

BRIEF-Vir Biotechnology Q4 EPS USD -0.31

Reuters
·
Feb 24

Vir posts Q4 revenue of USD 64.1 million up 5.17x

Reuters
·
Feb 24

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Feb 24

Vir Biotechnology reports new VIR-5500 data

TIPRANKS
·
Feb 24

Astellas, Vir announce global strategic collaboration

TIPRANKS
·
Feb 24

Stock Track | Vir Biotechnology Soars 5.52% After-Hours on Major Astellas Collaboration for Prostate Cancer Drug

Stock Track
·
Feb 24

Vir Biotechnology reports positive updated Phase 1 results for PSMA-targeting T-cell engager VIR-5500 in metastatic prostate cancer

Reuters
·
Feb 24

Vir Biotechnology Inc: Advancing Dose-Expansion Cohorts and Plan to Initiate Our Registrational Trial in 2027

THOMSON REUTERS
·
Feb 24

Vir Biotechnology Inc - Vir-5500 Shows Favorable Safety Profile With No Dose-Limiting Toxicities

THOMSON REUTERS
·
Feb 24

Vir Biotechnology: 82% Psa50 & 53% Psa90 Declines & Recist-Evaluable Objective Responses in ≥3,000 ΜG/Kg Q3w Dosing Cohorts With Vir-5500

THOMSON REUTERS
·
Feb 24

Vir Biotechnology Reports Positive Updated Phase 1 Results for Psma-Targeting, Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 in Patients With Metastatic Prostate Cancer

THOMSON REUTERS
·
Feb 24

BRIEF-Astellas & Vir Biotechnology Collaborate To Advance VIR-5500

Reuters
·
Feb 24

Astellas: Vir Biotechnology to GET $335 Mln in Upfront & Near-Term Milestone Payments, Will Split U.S. Profit/Loss Equally With Astellas

THOMSON REUTERS
·
Feb 24

Astellas: Under Terms of Vir Biotechnology's Licensing Deal With Sanofi, a Portion of Certain Collaboration Proceeds Will Be Shared With Sanofi

THOMSON REUTERS
·
Feb 24

Astellas collaborates with Vir to develop its experimental prostate cancer drug

Reuters
·
Feb 24

Astellas Pharma: Co & Vir Biotechnology Entered Global Strategic Collaboration to Advance Vir-5500 for Treatment of Prostate Cancer

THOMSON REUTERS
·
Feb 24